[go: up one dir, main page]

WO1997022360A3 - Regulation de synthese de proteines et procede de criblage pour agents pharmaceutiques - Google Patents

Regulation de synthese de proteines et procede de criblage pour agents pharmaceutiques Download PDF

Info

Publication number
WO1997022360A3
WO1997022360A3 PCT/GB1996/003186 GB9603186W WO9722360A3 WO 1997022360 A3 WO1997022360 A3 WO 1997022360A3 GB 9603186 W GB9603186 W GB 9603186W WO 9722360 A3 WO9722360 A3 WO 9722360A3
Authority
WO
WIPO (PCT)
Prior art keywords
agents
control
protein synthesis
screening method
pkb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1996/003186
Other languages
English (en)
Other versions
WO1997022360A2 (fr
Inventor
Philip Cohen
Dario Alessi
Darren Cross
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Dundee
Medical Research Council
Original Assignee
University of Dundee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9526083.2A external-priority patent/GB9526083D0/en
Priority claimed from GBGB9610272.8A external-priority patent/GB9610272D0/en
Priority claimed from GBGB9615066.9A external-priority patent/GB9615066D0/en
Priority to EP96943208A priority Critical patent/EP0868195A2/fr
Application filed by University of Dundee, Medical Research Council filed Critical University of Dundee
Priority to JP09522599A priority patent/JP2000502097A/ja
Priority to AU12004/97A priority patent/AU1200497A/en
Publication of WO1997022360A2 publication Critical patent/WO1997022360A2/fr
Publication of WO1997022360A3 publication Critical patent/WO1997022360A3/fr
Anticipated expiration legal-status Critical
Priority to US11/682,135 priority patent/US7897371B2/en
Priority to US13/021,048 priority patent/US20110275102A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Procédé de criblage d'agents capables d'affecter l'activité des kinases GSK3 et PKB, qui consiste à évaluer la phosphorylation de PKB sur deux acides aminés sur la molécule de PKB en particulier.
PCT/GB1996/003186 1995-11-16 1996-12-20 Regulation de synthese de proteines et procede de criblage pour agents pharmaceutiques Ceased WO1997022360A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU12004/97A AU1200497A (en) 1995-12-20 1996-12-20 Control of protein synthesis, and screening method for agents
JP09522599A JP2000502097A (ja) 1995-12-20 1996-12-20 タンパク質合成の制御、および作用薬のスクリーニング法
EP96943208A EP0868195A2 (fr) 1995-12-20 1996-12-20 Regulation de synthese de proteines et procede de criblage pour agents pharmaceutiques
US11/682,135 US7897371B2 (en) 1995-11-16 2007-03-05 Activation of mutated RAC-PK
US13/021,048 US20110275102A1 (en) 1995-11-16 2011-02-04 Activation of mutated rac-pk

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9526083.2A GB9526083D0 (en) 1995-12-20 1995-12-20 Method
GB9526083.2 1995-12-20
GBGB9610272.8A GB9610272D0 (en) 1996-05-16 1996-05-16 Method
GB9610272.8 1996-05-16
GBGB9615066.9A GB9615066D0 (en) 1996-07-18 1996-07-18 Method
GB9615066.9 1996-07-18

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09091763 A-371-Of-International 1996-12-20
US09/845,667 Continuation US20020065221A1 (en) 1995-11-16 2001-04-30 Control of protein synthesis, and screening method for agents

Publications (2)

Publication Number Publication Date
WO1997022360A2 WO1997022360A2 (fr) 1997-06-26
WO1997022360A3 true WO1997022360A3 (fr) 1997-07-31

Family

ID=27268041

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1996/003186 Ceased WO1997022360A2 (fr) 1995-11-16 1996-12-20 Regulation de synthese de proteines et procede de criblage pour agents pharmaceutiques

Country Status (5)

Country Link
EP (1) EP0868195A2 (fr)
JP (1) JP2000502097A (fr)
AU (1) AU1200497A (fr)
CA (1) CA2241080A1 (fr)
WO (1) WO1997022360A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9525702D0 (en) * 1995-12-15 1996-02-14 Ciba Geigy Ag Process for activating a kinase
US6057117A (en) * 1996-04-04 2000-05-02 Chiron Corporation Identification and use of selective inhibitors of glycogen synthase kinase 3
AU4920397A (en) 1996-10-11 1998-05-11 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
US6682920B1 (en) 1997-09-26 2004-01-27 Onyx Pharmaceuticals, Inc. Compositions and methods for identifying PKB kinase inhibitors
CA2298854A1 (fr) * 1997-09-26 1999-04-08 Onyx Pharmaceuticals, Inc. Compositions et techniques permettant d'identifier les inhibiteurs de la kinase de la pkb
SE9801530D0 (sv) * 1998-04-30 1998-04-30 Pharmacia & Upjohn Ab Method for screening
WO1999064062A1 (fr) * 1998-06-08 1999-12-16 Pharmacia & Upjohn Ab Nouvelle utilisation therapeutique d'amplificateurs de l'activite de la proteine kinase b (picb)
WO2001037852A2 (fr) * 1999-11-23 2001-05-31 Regeneron Pharmaceuticals, Inc. Methodes permettant d'inhiber l'atrophie ou de favoriser l'hypertrophie
ES2233691T3 (es) 2000-07-27 2005-06-16 F. Hoffmann-La Roche Ag Derivados de 3-indolil-4-fenil-1h-pirrol-2,5-diona como inhibidores de la glicogen sintasa kinasa-3beta.
WO2002024941A2 (fr) * 2000-09-22 2002-03-28 University Of Dundee Regulation de proteine kinase
IL144583A0 (en) * 2001-07-26 2002-05-23 Peptor Ltd Chimeric protein kinase inhibitors
CA2480880C (fr) 2002-04-08 2011-03-22 Merck & Co., Inc. Inhibiteurs de l'activite de akt
AU2003226271B2 (en) 2002-04-08 2007-10-18 Merck Sharp & Dohme Corp. Fused quinoxaline derivatives as inhibitors of Akt activity
CA2481229C (fr) 2002-04-08 2010-09-21 Merck & Co., Inc. Pyrazines substituees inhibitrices de l'akt
JP4394960B2 (ja) 2002-04-08 2010-01-06 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性阻害薬
GB0213614D0 (en) * 2002-06-13 2002-07-24 Novartis Forschungsstiftlung Z Purified PKB Kinae and uses thereof
JP2006507299A (ja) 2002-10-30 2006-03-02 メルク　エンド　カムパニー　インコーポレーテッド Ａｋｔ活性の阻害薬
CA2522430A1 (fr) 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibiteurs de l'activite akt
AU2004233828B2 (en) 2003-04-24 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
ATE461179T1 (de) 2003-04-24 2010-04-15 Merck Sharp & Dohme Hemmer der akt aktivität
ATE446752T1 (de) 2003-04-24 2009-11-15 Merck & Co Inc Hemmer der akt aktivität
KR20070073791A (ko) 2004-10-18 2007-07-10 암젠 인코포레이티드 티아디아졸 화합물 및 이의 사용방법
EP2173728A2 (fr) 2007-07-17 2010-04-14 Amgen Inc. Modulateurs hétérocycliques de pkb
CA2693473A1 (fr) 2007-07-17 2009-01-22 Amgen Inc. Thiadiazoles modulateurs de l'activite de pkb
WO2009125798A1 (fr) * 2008-04-09 2009-10-15 萬有製薬株式会社 Procédé d'identification par criblage d'une substance pharmaceutique candidate pour le traitement du cancer par activation de la voie de signalisation hedgehog
US10914728B2 (en) 2016-10-24 2021-02-09 Novo Nordisk A/S Bioassay for insulin formulations

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
B. BURGERING ET AL.: "Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction.", NATURE, vol. 376, no. 6541, 17 August 1995 (1995-08-17), LONDON, GB, pages 599 - 602, XP002032104 *
D. ALESSI ET AL.: "Mechanism of activation of protein kinase B by insulin and IGF-1.", THE EMBO JOURNAL, vol. 15, no. 23, 2 December 1996 (1996-12-02), OXFORD, GB, pages 6541 - 6551, XP002032108 *
D. ALESSI ET AL.: "Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase.", FEBS LETTERS, vol. 399, no. 3, 16 December 1996 (1996-12-16), AMSTERDAM, NL, pages 333 - 338, XP002032109 *
D. CROSS ET AL.: "Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B.", NATURE, vol. 378, no. 6559, 21 December 1995 (1995-12-21), LONDON, GB, pages 785 - 789, XP002025954 *
E. SIEGFRIED ET AL.: "Putative protein kinase product of the Drosophila segment-polarity gene zeste-white3.", NATURE, vol. 345, no. 6278, 28 June 1990 (1990-06-28), LONDON, GB, pages 825 - 829, XP002032106 *
H. KONISHI ET AL.: "Molecular cloning of rat RAC protein kinase alpha and beta and their association with protein kinase C gamma.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 205, no. 1, 30 November 1994 (1994-11-30), DULUTH, MN, USA, pages 817 - 825, XP002032107 *
T. FRANKE ET AL.: "The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase.", CELL, vol. 81, no. 5, 2 June 1995 (1995-06-02), CAMBRIDGE, MA, USA, pages 727 - 736, XP002032105 *

Also Published As

Publication number Publication date
EP0868195A2 (fr) 1998-10-07
AU1200497A (en) 1997-07-14
JP2000502097A (ja) 2000-02-22
WO1997022360A2 (fr) 1997-06-26
CA2241080A1 (fr) 1997-06-26

Similar Documents

Publication Publication Date Title
WO1997022360A3 (fr) Regulation de synthese de proteines et procede de criblage pour agents pharmaceutiques
AU1374797A (en) Adsorbent for phosphate from an aqueous medium, production and use of said adsorbent
AU5324996A (en) Protein kinase c inhibitors
AU1371999A (en) Benzothiazole protein tyrosine kinase inhibitors
AU7402196A (en) System and method for generating trusted, architecture specific, compiled versions of architecture neutral programs
AU2234695A (en) Rapid assays for protein kinase activity
AU8071698A (en) Novel heteroaryl compounds for the modulation of protein tyrosine enzyme relatedcellular signal transduction
EP0864647B8 (fr) Oxydase de fructosylaminoacides, son procede d'obtention, et methode d'essai des composes d'amadori utilisant ladite oxydase
WO1999020747A3 (fr) NOUVELLE KINASE HUMAINE POINT DE CONTROLE, hCDS1, COMPOSITIONS ET METHODES ASSOCIEES
AU7225396A (en) Method and system for determination of the pressure-volume relationship of the heart
WO1998005786A3 (fr) Enzymes de transformation afc1 et rce1: caax isoprenyles
ZA985026B (en) Method for enhancing the activity of an enzyme.
AU6707396A (en) Processes for the production of amidase
AU1291097A (en) A novel protein kinase required for ras signal transduction
AU3524995A (en) Method for treatment of cancers by regulating the activity of ras proteins
AU6960296A (en) Methods and articles for enhanced protein adsorption and fluid management on surfaces
AU4630297A (en) Map kinases: polypeptides, polynucleotides and uses thereof
AU9257998A (en) Method for enhancing the activity of an enzyme
AUPN720195A0 (en) Equine rhinovirus 1 proteins
AU2986395A (en) Method for screening compound libraries
WO1999015659A3 (fr) Enzymes de conjugaison de l'ubiquitine humaine
WO1999027080A3 (fr) Proteine kinase humaine et inhibiteurs de kinase
WO1997017448A3 (fr) Enzymes phospholipases a2/b cytosoliques independantes du calcium
AU5659296A (en) Pearl protein (nacrein) and process for producing the same
AU6123396A (en) Imidazo{1,5a}pyridine derived serine protease inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2241080

Country of ref document: CA

Ref country code: CA

Ref document number: 2241080

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 1997 522599

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996943208

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996943208

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1996943208

Country of ref document: EP